NO915115D0 - Cytokinsynteseinhibitorfaktor, antagonister for denne og fremgangsmaater for anvendelse derav - Google Patents

Cytokinsynteseinhibitorfaktor, antagonister for denne og fremgangsmaater for anvendelse derav

Info

Publication number
NO915115D0
NO915115D0 NO1991915115A NO915115A NO915115D0 NO 915115 D0 NO915115 D0 NO 915115D0 NO 1991915115 A NO1991915115 A NO 1991915115A NO 915115 A NO915115 A NO 915115A NO 915115 D0 NO915115 D0 NO 915115D0
Authority
NO
Norway
Prior art keywords
antagonists
cytochine
procedures
synthesis inhibitor
inhibitor factor
Prior art date
Application number
NO1991915115A
Other languages
English (en)
Other versions
NO301718B1 (no
NO915115L (no
Inventor
Timothy R Mosmann
Kevin W Moore
Martha W Bond
Paulo J M Vieira
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO915115D0 publication Critical patent/NO915115D0/no
Publication of NO915115L publication Critical patent/NO915115L/no
Publication of NO301718B1 publication Critical patent/NO301718B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO915115A 1989-06-28 1991-12-27 Fremgangsmåte for fremstilling av et polypeptid med cytokinsynteseinhiberingsfaktoraktivitet NO301718B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37266789A 1989-06-28 1989-06-28
US45395189A 1989-12-20 1989-12-20
PCT/US1990/003554 WO1991000349A1 (en) 1989-06-28 1990-06-28 Cytokine synthesis inhibitory factor, antagonists thereof, and methods of using same

Publications (3)

Publication Number Publication Date
NO915115D0 true NO915115D0 (no) 1991-12-27
NO915115L NO915115L (no) 1992-02-26
NO301718B1 NO301718B1 (no) 1997-12-01

Family

ID=27005854

Family Applications (1)

Application Number Title Priority Date Filing Date
NO915115A NO301718B1 (no) 1989-06-28 1991-12-27 Fremgangsmåte for fremstilling av et polypeptid med cytokinsynteseinhiberingsfaktoraktivitet

Country Status (22)

Country Link
EP (2) EP0405980A1 (no)
JP (1) JP2813063B2 (no)
KR (1) KR0183035B1 (no)
CN (3) CN1051393A (no)
AT (1) ATE180833T1 (no)
AU (1) AU635058B2 (no)
CA (1) CA2062763C (no)
CS (1) CS414591A3 (no)
DE (1) DE69033143T2 (no)
DK (1) DK0567450T3 (no)
ES (1) ES2132068T3 (no)
FI (1) FI107926B (no)
GR (1) GR3030404T3 (no)
HK (2) HK1040493B (no)
HU (1) HU216310B (no)
IL (1) IL94878A (no)
NO (1) NO301718B1 (no)
NZ (1) NZ234291A (no)
PT (1) PT94514B (no)
SG (1) SG52282A1 (no)
TW (1) TW218383B (no)
WO (1) WO1991000349A1 (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827513A (en) * 1990-06-29 1998-10-27 Schering Corporation Methods of treating insulin-dependent diabetes mellitus by administration of IL-10
DE69201128T2 (de) * 1991-01-16 1995-05-24 Schering Corp Behandlung von neoplastischen krankenheiten mit interleukin-10.
DK0567586T3 (da) * 1991-01-16 1995-12-04 Schering Corp Anvendelse af interleukin-10 ved adoptiv immunterapi af cancer
US6106823A (en) * 1991-01-16 2000-08-22 Schering Corporation Treatment of neoplastic disease with interleukin-10
DE4122402A1 (de) * 1991-07-04 1993-01-07 Schering Ag Verwendung von interleukin 10 zur herstellung von arzneimitteln mit tumorhemmender wirksamkeit
US5833976A (en) * 1991-08-06 1998-11-10 Schering Corporation Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity
DK0600970T3 (da) * 1991-08-06 2000-05-29 Schering Corp Anvendelse af interleukin-10-analoger eller -antagonister til behandling af endotoksin- eller superantigeninduceret tokscit
US6884410B1 (en) 1992-03-04 2005-04-26 Schering Corporation Methods for modulating antigen-specific immune responses
NZ249754A (en) * 1992-03-04 1997-06-24 Schering Corp Interleukin-10 and its use in inhibiting graft vs host disease or tissue rejection
US6277635B1 (en) 1992-03-04 2001-08-21 Schering Corporation Use of interleukin-10 to produce a population of suppressor cells
AU3801193A (en) * 1992-03-20 1993-10-21 Schering Corporation Use of interleukin-10 to induce the production of interleukin-1 receptor antagonist
KR0170037B1 (ko) * 1992-08-20 1999-02-01 에릭 에스. 딕커 인터루킨-4 및/또는 인터루킨-10을 함유하는 약제학적 조성물
US5601815A (en) * 1992-08-21 1997-02-11 Schering Corp IL-4 and IL-10 to downregulate delayed-type hypersensitivity and cytokine expresion by T-cells
EP0667789A1 (en) * 1992-09-18 1995-08-23 Schering Corporation Restoration of immunocompetency to t helper cells in hiv infected patients
DK0662837T3 (da) * 1992-10-01 1999-11-08 Schering Corp Anvendelse af IL-10 til forhindring af insulinafhængig diabetes mellitus
TW381026B (en) * 1993-01-13 2000-02-01 Schering Corp Method of extracorporally activating cytolytic activity of peripheral blood mononuclear cells and pharmaceutical composition comprising the activated peripheral blood mononuclear cells
CA2155109A1 (en) * 1993-02-01 1994-08-18 Daniel Abramowicz Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
US5328989A (en) * 1993-03-05 1994-07-12 Schering-Plough Purification of human interleukin-10 from a cell culture medium
US5449688A (en) * 1993-03-30 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services Method of treating chronic inflammatory diseases
IL110413A0 (en) * 1993-07-26 1994-10-21 Schering Corp Agonists and antagonists of human interleukin-10
US5650060A (en) * 1994-01-28 1997-07-22 Minnesota Mining And Manufacturing Company Ionically conductive agent, system for cathodic protection of galvanically active metals, and method and apparatus for using same
MX9606537A (es) * 1994-07-05 1997-12-31 Steeno Res Group As Inmunomoduladores.
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
CN101307106B (zh) * 1995-12-13 2013-06-12 儿童医学中心公司 内皮细胞增殖抑制剂及其应用方法
WO1997026278A1 (en) * 1996-01-18 1997-07-24 Steeno Research Group A/S Synthetic il-10 analogues
WO1997038695A1 (en) * 1996-04-17 1997-10-23 Prendergast Patrick T Dhea combination therapy
AU722570B2 (en) * 1996-09-06 2000-08-03 Schering Corporation Method for lowering cholesterol levels
AU5221998A (en) * 1997-04-17 1998-11-13 Patrick T. Prendergast Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors
US6465176B1 (en) * 1998-10-02 2002-10-15 Message Pharmaceuticals, Inc. Method for identifying compounds RNA/RNA binding protein interactions
AU5047600A (en) * 1999-05-27 2000-12-18 Schering Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
EP1283722A1 (en) 2000-03-31 2003-02-19 Idec Pharmaceuticals Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
US8491912B2 (en) 2010-06-16 2013-07-23 Allergan, Inc. Methods of treating ocular and other diseases with Syn-134R polypeptide
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
CA3045944A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3054156A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
CN113348011B (zh) 2018-11-19 2023-04-18 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
GB202003428D0 (en) * 2020-03-10 2020-04-22 Univ Dundee IL-10 mutiens

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78197A (en) * 1985-03-22 1991-07-18 Genentech Inc Nucleic acid encoding tgf-beta and its uses
IE62650B1 (en) * 1989-08-04 1995-02-22 David & Sons Ltd Dispensing apparatus
MX9203409A (es) * 1989-12-20 1992-07-01 Schering Corp Proteinas bcrfi como inhibidores de la gama interferona.

Also Published As

Publication number Publication date
ES2132068T3 (es) 1999-08-16
DE69033143T2 (de) 1999-10-21
AU635058B2 (en) 1993-03-11
HK1040493A1 (en) 2002-06-14
JPH04502560A (ja) 1992-05-14
KR0183035B1 (ko) 1999-04-01
IL94878A (en) 2003-01-12
CS414591A3 (en) 1992-12-16
CN1051393A (zh) 1991-05-15
CA2062763C (en) 2010-01-05
EP0567450A1 (en) 1993-11-03
FI107926B (fi) 2001-10-31
HK1008834A1 (en) 1999-05-21
AU6077090A (en) 1991-01-17
PT94514A (pt) 1991-04-18
FI916126A0 (fi) 1991-12-27
DE69033143D1 (de) 1999-07-08
GR3030404T3 (en) 1999-09-30
ATE180833T1 (de) 1999-06-15
KR920701437A (ko) 1992-08-11
HK1040493B (zh) 2005-12-16
CN1317569A (zh) 2001-10-17
HK1040531A1 (en) 2002-06-14
NO301718B1 (no) 1997-12-01
SG52282A1 (en) 1998-09-28
CN1198642C (zh) 2005-04-27
TW218383B (no) 1994-01-01
EP0567450B1 (en) 1999-06-02
NO915115L (no) 1992-02-26
CN1318589C (zh) 2007-05-30
HU906705D0 (en) 1992-03-30
EP0405980A1 (en) 1991-01-02
NZ234291A (en) 1992-11-25
CA2062763A1 (en) 1990-12-29
CN1317343A (zh) 2001-10-17
HU216310B (hu) 1999-06-28
HK1040531B (zh) 2008-01-11
DK0567450T3 (da) 1999-12-13
WO1991000349A1 (en) 1991-01-10
IL94878A0 (en) 1991-04-15
PT94514B (pt) 1998-02-27
HUT61048A (en) 1992-11-30
JP2813063B2 (ja) 1998-10-22

Similar Documents

Publication Publication Date Title
NO915115L (no) Cytokinsynteseinhibitorfaktor, antagonister for denne og fremgangsmaater for anvendelse derav
EP0335901A4 (en) Methods and compositions for the treatment of non-ige-mediated diseases
FI935585A0 (fi) Pyrrolopyrimidiner
ATE296799T1 (de) P38-inhibitoren
NO965621D0 (no) Nye hIL-4-mutantproteiner som antagonister eller partielle agonister for det humane interleukin 4
DK0502956T3 (da) Fremstilling af en rekombinant human interleukin-1-inhibitor.
DK20690D0 (da) Alkoxy-1,2,4-triazolo(1,5-c)pyrimidin-2-sulfonamider, fremgangsmaade til deres fremstilling og mellemprodukter
DK0504177T3 (da) IL-11, et pattedyrcytokin
DK0604418T3 (da) Isolerede viralproteincytokinantagonister
IT1231549B (it) Procedimento per la produzione di semilavorati di cuoio
NO922456D0 (no) Bcrf1-proteiner som inhibitorer av interferon-gamma
ES2128348T3 (es) Obtencion de composiciones para el tratamiento de alteraciones de la proliferacion celular.
GR1000664B (el) Παρασκευη ενωσεων αντι-υπερχοληστερολαιμικης τετραζολης και ενδιαμεσων αυτων.
IT8645710A0 (it) Procedimento e dispositivo per la fabbricazione di mobili per apparecchi frigoriferi.
DK0656889T3 (da) 9-chlorprostaglandinestere og -amider og deres anvendelse ved fremstilling af lægemidler
DE60230044D1 (de) Isochinolin-inhibitoren von p38
ITMI931034A1 (it) Processo per la preparazione di proteine inibenti i ribosomi
IT210914Z2 (it) Piano autoportante per la costruzione di mobili,quali tavoli,panche e simili
ITTO930477A1 (it) Procedimento per la realizzazione di diaframmi, basamenti e piazzali monolitici e relativa attrezzatura.
BR8700332A (pt) Cinto elastico para exercicios fisioterapicos ou assemelhados
MY129421A (en) INHIBITORS OF p38

Legal Events

Date Code Title Description
MK1K Patent expired